Cessatech announces superior simulated pain efficacy in children

Cessatech announces the final simulated efficacy data in children with CT001 from the abstract… Cessatech announce s the final simulated efficacy data in children with CT001 from the abstract that will be presented at the Population Approach Group Europe ( PAGE ) conference in Rome Italy , during 2 6 – 28 June 2024 . The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and placebo respectively. Estimates for the opioid sparing effect of ketamine showed a need for more than double the sufentanil exposure to get the same overall effect seen with the treatment of CT001. The data supports the earlier reported data from the Dental Study 0205 showing the effectiveness of treatment with CT001. The full simulated data set will be presented at the PAGE conference in Rome 26-28 June. https://cessatech.com/wp-content/uploads/2024/06/ct001-data-in-children_LS.mp4 Press release 240306 – CT001 simulated pain in children Jes Trygved, CEO, Cessatech “We are very pleased with the final simulated results and the opportunity to present them at the prestigious PAGE conference. The data strongly support our hypothesis that CT001 is very effective in children relative to its active comparators and will be instrumental in our further development. A great effort by the team and CT001 is now one step closer to finalize the clinical program and becoming available to hospitals and the children that really need approved, easy to administer pain relief.” Related articles Releases 27. August, 2026 CT001 ready for shipment to initial U.S. hospitals as launch activities commence Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with... Read more Releases 24. July, 2026 Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu See also the updated Q&A documentation related to the Release: Link The European Medicines... Read more Releases 12. June, 2026 Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children ... Read more Stay up to date! Subscribe and get notified on Cessatech's latest news. An acceptance email will be sent to you, please check your spam. Please leave this field empty Almost there! Please check your inbox to confirm your subscription to Cessatech.

The release as fetched from its publisher. cessatech.com ↗